Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: August 13, 2022

Details for Patent: 7,777,050

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 7,777,050
Title:N3 alkylated benzimidazole derivatives as MEK inhibitors
Abstract: Disclosed are compounds of the Formula I ##STR00001## and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R.sup.1, R.sup.2, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Inventor(s): Wallace; Eli M. (Lyons, CO), Lyssikatos; Joseph P. (Superior, CO), Marlow; Allison L. (Boulder, CO), Hurley; T. Brian (Boulder, CO)
Assignee: Array BioPharma Inc. (Boulder, CO)
Application Number:12/050,827
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 7,777,050

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,777,050

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 038971 See Plans and Pricing
Argentina 045738 See Plans and Pricing
Argentina 090143 See Plans and Pricing
Argentina 090144 See Plans and Pricing
Austria 449605 See Plans and Pricing
Australia 2003218157 See Plans and Pricing
Australia 2004270166 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.